Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, October 1 '25)

Image
By G.M.

 


    Clin Infect Dis

  1. CALABRESE C, Wang Y, Duggal A, Huang S, et al
    Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.
    Clin Infect Dis. 2025 Oct 24:ciaf521. doi: 10.1093.
    PubMed         Abstract available

  2. FONG Y, Huang Y, Huang Y, Woo W, et al
    Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine.
    Clin Infect Dis. 2025 Oct 25:ciaf558. doi: 10.1093.
    PubMed         Abstract available

  3. KABORE JL, Laffont B, Diop M, Tardif MR, et al
    Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019-Associated Hospitalization: A Population-Based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2025 Oct 29:ciaf145. doi: 10.1093.
    PubMed         Abstract available


  4. Retraction and replacement of: Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2025 Oct 29:ciaf144. doi: 10.1093.
    PubMed        

  5. RATTANAPITOON NK, La N, Thanchonnang C, Rattanapitoon SK, et al
    Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps.
    Clin Infect Dis. 2025 Oct 31:ciaf605. doi: 10.1093.
    PubMed        


    Int J Infect Dis

  6. MARKING U, Wahlstrom E, Holm J, Walther S, et al
    Risk factors for hospitalisation and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study.
    Int J Infect Dis. 2025 Oct 27:108156. doi: 10.1016/j.ijid.2025.108156.
    PubMed         Abstract available

  7. ZHANG S, Yang M, Zhou W, Yao Y, et al
    Changes of Dynamics of Influenza before and after COVID-19 Pandemic: A Global Study in Eight Regions.
    Int J Infect Dis. 2025 Oct 29:108173. doi: 10.1016/j.ijid.2025.108173.
    PubMed         Abstract available


    J Infect

  8. HAN S, Liu Y, Xing B, Yang Y, et al
    Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Infections: A Systematic Review and Meta-analysis.
    J Infect. 2025 Oct 29:106645. doi: 10.1016/j.jinf.2025.106645.
    PubMed         Abstract available

  9. ZHAN JY, Ren L, Li CK, Zhong L, et al
    Exhausted KLRG1(hi) CD8(+) T and Pathogenic GZMA(+) Th17 Cells Are Associated with the Mild Mycoplasma pneumoniae Pneumonia in Children.
    J Infect. 2025 Oct 29:106642. doi: 10.1016/j.jinf.2025.106642.
    PubMed         Abstract available

  10. SANO K, Kimura Y, Hirahata K, Kato H, et al
    SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID.
    J Infect. 2025 Oct 23:106641. doi: 10.1016/j.jinf.2025.106641.
    PubMed        


    J Med Virol

  11. YUAN L, Wang B, Huang YW
    Regulation of Apoptosis and PANoptosis by Coronavirus: An Overview.
    J Med Virol. 2025;97:e70672.
    PubMed         Abstract available

  12. DALEXIS RD, Xu Y, Moshirian Farahi SMM, Beogo I, et al
    COVID-19 Vaccine Mistrust, Racial Discrimination, and Conspiracy Beliefs Among Parents in Canada: Implications for Public Health.
    J Med Virol. 2025;97:e70673.
    PubMed         Abstract available

  13. CHEN R, Hui KPY, Nicholls JM, Ip MSM, et al
    Cigarette Smoke Deteriorates SARS-CoV-2 Infection-Induced Lung Injury.
    J Med Virol. 2025;97:e70671.
    PubMed         Abstract available


    J Virol

  14. DETTE A, Moers F, Mayr T, Stillfried Sv, et al
    Differential expression of viral entry protein neuropilin 1 (NRP1) and neuropilin 2 (NRP2) in fatal COVID-19.
    J Virol. 2025 Oct 29:e0138425. doi: 10.1128/jvi.01384.
    PubMed         Abstract available

  15. JOHNSON KEE, Stein S, Boateng RA, Jain S, et al
    Tissue tropism and functional adaptation of the SARS-CoV-2 spike protein in a fatal case of COVID-19.
    J Virol. 2025 Oct 31:e0085725. doi: 10.1128/jvi.00857.
    PubMed         Abstract available

  16. ZHANG D, Yuan Y, Hu G, Xie Y, et al
    Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.
    J Virol. 2025 Oct 31:e0145225. doi: 10.1128/jvi.01452.
    PubMed         Abstract available


    JAMA

  17. WILSON KT, Esposito ML, Martinez A
    Life Expectancy After the COVID-19 Pandemic.
    JAMA. 2025 Oct 27. doi: 10.1001/jama.2025.16403.
    PubMed        

  18. ABBASI J
    New Guidance on Cardiovascular Disease and COVID-19-From Infection to Long COVID to Vaccination.
    JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.18834.
    PubMed        

  19. SCHWANDT H, Kowarski J, Woolf SH
    Life Expectancy After the COVID-19 Pandemic-Reply.
    JAMA. 2025 Oct 27. doi: 10.1001/jama.2025.16405.
    PubMed        

  20. PANT S
    First-Trimester COVID-19 Vaccination Not Associated With Congenital Risks.
    JAMA. 2025 Oct 31. doi: 10.1001/jama.2025.17533.
    PubMed        


    Lancet

  21. SEDKY J, Gardner A, Ivers LC
    Loans dominated COVID-19 funding: it's time to adjust.
    Lancet. 2025;406:1946.
    PubMed        


    Lancet Infect Dis

  22. BAGER P, Svalgaard IB, Christiansen LE, Lomholt FK, et al
    COVID-19 versus influenza burden in Denmark in the 2024-25 season.
    Lancet Infect Dis. 2025 Oct 27:S1473-3099(25)00604.
    PubMed        

  23. SYMES R, Whitaker HJ, Ahmad S, Arnold D, et al
    Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.
    Lancet Infect Dis. 2025 Oct 27:S1473-3099(25)00546.
    PubMed         Abstract available


    N Engl J Med

  24. SCOTT J, Abers MS, Marwah HK, McCann NC, et al
    Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
    N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMsa2514268.
    PubMed         Abstract available


    Nature

  25. SMITH J
    Daily briefing: People with cancer lived longer if they'd had a COVID-19 vaccine.
    Nature. 2025 Oct 23. doi: 10.1038/d41586-025-03496.
    PubMed        


    Pol J Radiol

  26. RIZZETTO F, Berta L, Zorzi G, Travaglini F, et al
    Optimising strategies for artificial intelligence-assisted classification of viral pneumonias on CT imaging: a comparative study of selective and default approaches.
    Pol J Radiol. 2025;90:e384-e393.
    PubMed         Abstract available


    Science

  27. BRETT TS, Rohani P
    Collateral effects of COVID-19 pandemic control on the US infectious disease landscape.
    Science. 2025;390:510-515.
    PubMed         Abstract available

  28. DURRHEIM DN
    Broad benefits of the COVID-19 pandemic response.
    Science. 2025;390:442.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »